Navigation Links
Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
Date:10/9/2008

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced it has been named among the best biopharmaceutical companies in the world, according to Science magazine's annual survey of Top Employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. With a 2008 ranking of eighth, the Company is in the top ten for the first time, moving up from a 2007 ranking of 14.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"This top ten ranking underscores Millennium's commitment not only to breakthrough science, but also to its employees and overall working environment," said Stephen Gansler, Senior Vice President, Human Resources, Millennium. "It is now more important than ever for us to keep up this positive work culture as we recruit for the hundreds of new additions over the next few months."

Respondents to the web-based survey were asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change and a research-driven environment. The 2008 survey sought to identify the companies with the best reputations as employers, based on nearly 4,000 survey responses from readers of Science and other respondents in industry. Twenty percent of the respondents came from outside the United States, primarily Western Europe, and 92 percent worked in private industry. For the complete business office feature with individual company rankings, please visit: http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articl es/ 2008_10_10/science.opms.r0800061.

Millennium was acquired by Takeda Pharmaceutical Company Limited in May, 2008.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, http://www.millennium.com.

Editor's Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com

Media Contact:

Manisha Pai

(617)551-7877

manisha.pai@mpi.com


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
2. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
3. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
4. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
5. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
6. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
7. Millennium Announces $200,000 Purchase Order From Greek Distributor
8. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
10. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
11. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... VANCOUVER, British Columbia and MENLO PARK, ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies, today announced that it will present at the ... on Monday, February 8, 2016 at 10:00 a.m. EST in ... Jeffrey Bacha , DelMar,s president and CEO, will provide an ...
(Date:2/4/2016)... , Feb. 4, 2016 Sinovac Biotech Ltd. ... leading provider of biopharmaceutical products in China ... its board of directors received on February 4, 2016 ... from a consortium comprised of PKU V-Ming ( ... Co., Ltd., CICC Qianhai Development ( Shenzhen ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, Inc ... the first pluripotent stem cell-derived islet replacement therapy ... clinical-stage development, today announced that ViaCyte and Janssen ... of Johnson & Johnson, have agreed to consolidate ... ViaCyte.  The agreement provides ViaCyte with an exclusive ...
(Date:2/3/2016)... NEW YORK and HOLLISTON, Mass., Feb. 3, ... (Nasdaq: HART ), a biotechnology company developing ... esophagus, trachea and bronchus, today announced that CEO ... BIO CEO & Investor Conference on ... in New York City . ...
Breaking Biology Technology:
(Date:1/18/2016)... 18, 2016  Extenua Inc., a pioneering developer ... use and access of ubiquitous on-premise and cloud ... American Cyber.  ... transformational C4ISR and Cyber initiatives in support of ... proven technology solutions," said Steve Visconti , ...
(Date:1/11/2016)... CHICAGO , Jan. 11, 2016  higi, ... via nearly 10,000 retail locations, web and mobile, ... than $40 million from existing investors. ... will be devoted to further innovate higi,s health ... app and web portal – including expanding services ...
(Date:1/7/2016)... United States District Court in Illinois ... interpret a biometric privacy statute in a decision allowing ... website Shutterfly brought by the law firm Carey Rodriguez Milian ... INC.; and THISLIFE, INC ( N.D. Ill ., Case: ... Biometric Privacy Act by collecting and scanning face geometry ...
Breaking Biology News(10 mins):